In a 59‑year‑old male presenting with urinary dribbling, hesitancy, frequency >5 times daily, nocturia 1–2 times, weak stream requiring straining, no hematuria, and an enlarged non‑nodular prostate on digital rectal examination, which diagnostic investigations should be requested to confirm benign prostatic hyperplasia and exclude prostate cancer?

Diagnostic Investigations to Confirm BPH and Exclude Prostate Cancer

To confirm benign prostatic hyperplasia and exclude prostate cancer in this patient, request: (1) urinalysis and (2) serum prostate-specific antigen (PSA) measurement. 1, 2

Primary Diagnosis: Benign Prostatic Hyperplasia

The clinical presentation—voiding difficulties (hesitancy, weak stream, straining) combined with storage symptoms (frequency >5×/day, nocturia 1-2×)—alongside an enlarged, soft, non-nodular prostate on digital rectal examination establishes the presumptive diagnosis of benign prostatic enlargement. 2 The soft, non-tender texture on DRE effectively rules out prostate cancer, which typically presents with a hard, nodular, or indurated gland. 2

Essential Diagnostic Tests

1. Urinalysis (Dipstick or Microscopic Examination)

Urinalysis is mandatory to screen for hematuria, urinary tract infection, and other bladder pathology. 1

• Bladder cancer, carcinoma in situ, urinary tract infections, urethral strictures, distal urethral stones, and bladder stones can all produce lower urinary tract symptoms mimicking BPH. 1
• Although hematuria or pyuria is not universally present in these conditions, a normal urinalysis makes these alternative diagnoses significantly less likely. 1
• The absence of hematuria in this patient is reassuring but must be confirmed objectively. 1

2. Serum Prostate-Specific Antigen (PSA)

PSA measurement should be offered to this 59-year-old patient who has at least a 10-year life expectancy. 1, 2

• PSA serves two critical purposes: (1) excluding prostate cancer as a cause of lower urinary tract symptoms, and (2) predicting BPH progression risk. 2
• Men with higher serum PSA levels have increased risk of future prostate growth, symptom deterioration, acute urinary retention, and need for BPH-related surgery. 1
• PSA testing combined with the already-performed normal DRE provides reasonable confidence in excluding clinically significant prostate cancer. 3
• Approximately 25% of men with BPH have PSA >4 ng/mL, so the test must be interpreted in clinical context. 1

Why These Two Tests Are Sufficient

The American Urological Association guidelines emphasize focusing diagnostic evaluation on tests that will directly impact patient management. 1 This patient already has:

• Completed history documenting classic obstructive and storage symptoms 2
• Digital rectal examination revealing enlarged, soft, non-nodular prostate that excludes locally advanced cancer 1, 2
• No hematuria by history (to be confirmed by urinalysis) 1

Tests NOT Recommended at This Stage

Urodynamics and transrectal ultrasound should be limited to situations where results will benefit the patient, such as selection for surgery. 1 These are not needed for initial diagnosis confirmation. 1

Urine cytology is optional and primarily indicated for men with predominantly irritative symptoms and smoking history or other risk factors for bladder cancer. 1 This patient's presentation is predominantly obstructive, making cytology unnecessary initially. 1

Imaging and endoscopy have specific indications such as dipstick hematuria, but are not routine diagnostic requirements. 1

Common Pitfalls to Avoid

• Do not order extensive imaging or urodynamics for initial diagnosis—these tests should be reserved for patients being considered for surgery or those with atypical presentations. 1
• Do not skip PSA testing in appropriate candidates—this 59-year-old working male (Jeepney driver) clearly has >10-year life expectancy and warrants cancer screening. 1, 2
• Do not rely solely on DRE to exclude cancer—while the soft, non-nodular prostate is reassuring, PSA adds important prognostic information about both cancer risk and BPH progression. 1, 2

Additional Recommended Assessment (Not Diagnostic Tests)

While not diagnostic procedures per se, quantifying symptom severity using the International Prostate Symptom Score (IPSS) or AUA Symptom Index is recommended to guide treatment decisions and establish baseline severity. 2, 4 This validated questionnaire provides objective documentation of symptom burden. 2, 4